Lexaria Bioscience Corp. (LEXX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Lexaria Bioscience's Phase 1b study starts patient dosing, says H.C. Wainwright
H.C. Wainwright reiterates a Buy rating and $10 price target on Lexaria Bioscience shares after the company announced that the Phase 1b 12-week chronic study in Australia has started patient dosing as planned. The GLP-1-H24-4 study includes four planed DehydraTECH formulation arms and one Rybelsus comparator control arm and is slated to enroll 20 20 overweight, obese, pre- or type 2 diabetic patients for each of arms 1-4 at seven clinical sites, with the DehydraTECH-tirzepatide Arm 5 to be added at a later date if supported by positive results from the separate ongoing study GLP-1- H24-3, the analyst tells investors in a research note. Positive results from this study could expand the application of the DehydraTECH delivery technology in the GLP-1 sector, the firm says.
Lexaria Forms New Scientific Advisory Board
North American drug delivery development experts added to help guide Lexaria's strategic plans KELOWNA, BC / ACCESSWIRE / December 18, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the creation of its new Scientific Advisory Board ("SAB") to assist in guiding Lexaria's rapid drug delivery platform technology and strategic development plans within the pharmaceutical industry. The SAB will initially be comprised of four people and the Chairman of the SAB will be Lexaria's President and Chief Scientific Officer, John Docherty.
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
Dr. Gibson joining Lexaria's new scientific advisor board KELOWNA, BC / ACCESSWIRE / December 17, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appointment of Dr. Michael Gibson as its new Chief Medical Advisor. Dr. Gibson will collaborate directly with President John Docherty as Lexaria's patented DehydraTECH drug delivery platform continues to expand its applications in GLP-1 and hypertension.
Lexaria Bioscience Corp. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MC mike Chen Byrne Asset Management LLC | 105,500 | $101,389.64 | $67,520 | -$33,869.64 | -33.41% |
 Christopher C. Powers Farther Finance Advisors, LLC | 166 | $452 | $106.24 | -$345.76 | -76.5% |
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 382 | $653 | $244.48 | -$408.52 | -62.56% |
Lexaria Bioscience Corp. (LEXX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lexaria Bioscience Corp. ever had a stock split?
Lexaria Bioscience Corp. Profile
| Biotechnology Industry | Healthcare Sector | Richard C. Christopher CEO | NASDAQ (CM) Exchange | 52886N406 CUSIP |
| CA Country | 7 Employees | - Last Dividend | 12 Jan 2021 Last Split | 10 Oct 2006 IPO Date |
Overview
Lexaria Bioscience Corp. positions itself within the biotechnology landscape, focusing on the development and out-licensing of its pioneering drug delivery technology, DehydraTECH. This technology epitomizes innovation in the way it enhances the entry of lipophilic molecules or active pharmaceutical ingredients into the bloodstream. By amalgamating these molecules with specific long-chain fatty acids and carrier compounds, DehydraTECH not only boosts their effectiveness but also advocates for reduced dosages and promotes healthier methods of oral ingestation. Since its inception in 2004, Lexaria Bioscience Corp. has established its headquarters in Kelowna, Canada, where it continuously explores the potential of its DehydraTECH technology across various therapeutic indications and product formats.
Products and Services
- DehydraTECH Technology - Lexaria's flagship innovation, facilitating improved bioavailability and efficiency of lipophilic molecules. This technology is adept at:
Enhancing the delivery of active pharmaceutical ingredients into the bloodstream, thereby ensuring increased effectiveness and permitting lower doses. It's particularly beneficial for a wide array of active molecules, ranging from fat-soluble vitamins and pain medications to hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids.
- Applications in Therapeutic Indications - DehydraTECH's scope spans beyond merely enhancing delivery mechanisms. Its utilization extends to:
Investigating therapeutic applications in critical areas such as hypertension, heart disease, and diabetes. By leveraging the technology's unique delivery system, Lexaria aims to revolutionize treatment methodologies and improve patient outcomes in these significant health domains.
- Versatile Product Formats - Recognizing the varied needs of the pharmaceutical, nutraceutical, and consumer goods sectors, Lexaria has adapted DehydraTECH to suit diverse formats, including:
Pharmaceuticals, nutraceuticals, over-the-counter medications, and consumer packaged goods. This adaptability underscores Lexaria's commitment to broadening the application of its technology across different products and markets, ensuring users have access to more efficient and healthier ingestion methods.
